Aegle Therapeutics
Aegle Therapeutics is a biotechnology company developing novel therapies using extracellular vesicles from mesenchymal stem cells for severe dermatological disorders, with a focus on dystrophic epidermolysis bullosa.
Company Overview
Aegle Therapeutics is dedicated to developing novel therapies using extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs). These EVs deliver therapeutic biomolecules to diseased and damaged cells. Focusing on conditions with significant unmet medical needs, the company aims to treat disorders such as dystrophic epidermolysis bullosa (DEB) and other severe dermatological conditions. Their platform technology holds potential for a broad range of therapeutic applications.
Lead Product: AGLE-102
Aegle Therapeutics' lead product, AGLE-102, is a therapeutic composite made up of EVs, including exosomes, which are isolated from MSCs through proprietary EV harvesting technology. AGLE-102 is currently undergoing a phase 1/2 clinical study for individuals with Recessive Dystrophic Epidermolysis Bullosa (RDEB). The FDA has granted AGLE-102 both Rare Pediatric Disease Designation and Fast Track Status for the treatment of Dystrophic Epidermolysis Bullosa.
Current Clinical Studies
Aegle Therapeutics is actively enrolling participants for a phase 1/2 clinical study of their lead product, AGLE-102, aimed at treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). This study is crucial for evaluating the safety and effectiveness of AGLE-102 in a clinical setting, potentially paving the way for future treatments based on their EV platform technology.
Funding and Grants
Aegle Therapeutics successfully completed a $6.5 million Series A financing round, which is instrumental in advancing their research and development efforts. Additionally, they have been awarded a grant by the U.S. Department of Defense to support the development of AGLE-102, underscoring the potential impact and significance of their work in therapeutic innovations.
Office Locations
Aegle Therapeutics is headquartered at 400 TradeCenter, Suite 5900, Woburn, MA 01801. They also maintain an additional office located at 1951 NW 7th Ave, Suite 160 / #152, Miami, FL 33136. These locations support the company's research, development, and administration operations.